3 High Dividend Dow Jones Stocks
Thanks to surging stock prices over the past two years,…
Sell
29
SNNUF Quote, Financials, Valuation and Earnings
Last price:
$12.21
Seasonality move
:
-2.63%
Day range:
$12.21 - $12.21
52-week range:
$11.49 - $15.70
Dividend yield:
3.07%
P/E ratio:
34.07x
P/S ratio:
1.89x
P/B ratio:
2.05x
Volume:
3.8K
Avg. volume:
1.7K
1-year change:
-9.48%
Market cap:
$10.6B
Revenue:
$5.5B
EPS (TTM):
$0.35
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SNNUF
Smith & Nephew PLC
|
$1.5B | -- | -- | -- | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
$8.8M | -$0.15 | 4199.24% | -9.44% | $2.27 |
|
AUTL
Autolus Therapeutics PLC
|
$3M | -$0.24 | -61.82% | -46.14% | $10.45 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.97 |
|
NCNA
NuCana PLC
|
-- | -$0.09 | -- | -98.11% | $64.50 |
|
VRNA
Verona Pharma PLC
|
$16.5M | -$0.25 | -- | -2.08% | $47.29 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SNNUF
Smith & Nephew PLC
|
$12.21 | -- | $10.6B | 34.07x | $0.14 | 3.07% | 1.89x |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.65 | $2.27 | $166.3M | -- | $0.00 | 0% | 0.91x |
|
AUTL
Autolus Therapeutics PLC
|
$2.60 | $10.45 | $691.9M | -- | $0.00 | 0% | -- |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$4.45 | $17.97 | $2.6M | -- | $0.00 | 0% | 4.01x |
|
NCNA
NuCana PLC
|
$1.27 | $64.50 | $5M | -- | $0.00 | 0% | -- |
|
VRNA
Verona Pharma PLC
|
$44.81 | $47.29 | $3.7B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SNNUF
Smith & Nephew PLC
|
40.01% | -0.469 | 31.16% | 1.11x |
|
ADAP
Adaptimmune Therapeutics PLC
|
38.4% | 4.431 | 20.51% | 3.54x |
|
AUTL
Autolus Therapeutics PLC
|
-- | 3.664 | -- | 17.97x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 0.100 | -- | 1.20x |
|
NCNA
NuCana PLC
|
-- | 1.546 | -- | -- |
|
VRNA
Verona Pharma PLC
|
47.91% | -1.186 | 5.1% | 12.47x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SNNUF
Smith & Nephew PLC
|
-- | -- | 3.68% | 5.85% | -- | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$14.7M | -55.22% | -67.8% | -38.33% | -$54.9M |
|
AUTL
Autolus Therapeutics PLC
|
-- | -$67.7M | -80.74% | -80.74% | -331.28% | -$86.3M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana PLC
|
-- | -$6.6M | -- | -- | -- | -$6.4M |
|
VRNA
Verona Pharma PLC
|
$5.1M | -$39.1M | -55.17% | -74.15% | -583.75% | -$62.7M |
Smith & Nephew PLC vs. Competitors
-
Which has Higher Returns SNNUF or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -- compared to Smith & Nephew PLC's net margin of -43.07%. Smith & Nephew PLC's return on equity of 5.85% beat Adaptimmune Therapeutics PLC's return on equity of -67.8%.
Company Gross Margin Earnings Per Share Invested Capital SNNUFSmith & Nephew PLC-- -- $8.7B ADAPAdaptimmune Therapeutics PLC-- -$0.06 $129.9M -
What do Analysts Say About SNNUF or ADAP?
Smith & Nephew PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $2.27 which suggests that it could grow by 248.72%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Smith & Nephew PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Smith & Nephew PLC.
Company Buy Ratings Hold Ratings Sell Ratings SNNUFSmith & Nephew PLC0 0 0 ADAPAdaptimmune Therapeutics PLC4 2 0 -
Is SNNUF or ADAP More Risky?
Smith & Nephew PLC has a beta of 0.662, which suggesting that the stock is 33.815% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.236, suggesting its more volatile than the S&P 500 by 123.631%.
-
Which is a Better Dividend Stock SNNUF or ADAP?
Smith & Nephew PLC has a quarterly dividend of $0.14 per share corresponding to a yield of 3.07%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew PLC pays 124.34% of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNNUF or ADAP?
Smith & Nephew PLC quarterly revenues are --, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $40.9M. Smith & Nephew PLC's net income of -- is lower than Adaptimmune Therapeutics PLC's net income of -$17.6M. Notably, Smith & Nephew PLC's price-to-earnings ratio is 34.07x while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew PLC is 1.89x versus 0.91x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNNUFSmith & Nephew PLC1.89x 34.07x -- -- ADAPAdaptimmune Therapeutics PLC0.91x -- $40.9M -$17.6M
-
Which has Higher Returns SNNUF or AUTL?
Autolus Therapeutics PLC has a net margin of -- compared to Smith & Nephew PLC's net margin of -522.15%. Smith & Nephew PLC's return on equity of 5.85% beat Autolus Therapeutics PLC's return on equity of -80.74%.
Company Gross Margin Earnings Per Share Invested Capital SNNUFSmith & Nephew PLC-- -- $8.7B AUTLAutolus Therapeutics PLC-- -$0.31 $582M -
What do Analysts Say About SNNUF or AUTL?
Smith & Nephew PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $10.45 which suggests that it could grow by 301.92%. Given that Autolus Therapeutics PLC has higher upside potential than Smith & Nephew PLC, analysts believe Autolus Therapeutics PLC is more attractive than Smith & Nephew PLC.
Company Buy Ratings Hold Ratings Sell Ratings SNNUFSmith & Nephew PLC0 0 0 AUTLAutolus Therapeutics PLC8 0 0 -
Is SNNUF or AUTL More Risky?
Smith & Nephew PLC has a beta of 0.662, which suggesting that the stock is 33.815% less volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 2.049, suggesting its more volatile than the S&P 500 by 104.921%.
-
Which is a Better Dividend Stock SNNUF or AUTL?
Smith & Nephew PLC has a quarterly dividend of $0.14 per share corresponding to a yield of 3.07%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew PLC pays 124.34% of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNNUF or AUTL?
Smith & Nephew PLC quarterly revenues are --, which are smaller than Autolus Therapeutics PLC quarterly revenues of $10.1M. Smith & Nephew PLC's net income of -- is lower than Autolus Therapeutics PLC's net income of -$82.1M. Notably, Smith & Nephew PLC's price-to-earnings ratio is 34.07x while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew PLC is 1.89x versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNNUFSmith & Nephew PLC1.89x 34.07x -- -- AUTLAutolus Therapeutics PLC-- -- $10.1M -$82.1M
-
Which has Higher Returns SNNUF or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -- compared to Smith & Nephew PLC's net margin of --. Smith & Nephew PLC's return on equity of 5.85% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital SNNUFSmith & Nephew PLC-- -- $8.7B BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About SNNUF or BDRX?
Smith & Nephew PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 303.85%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Smith & Nephew PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Smith & Nephew PLC.
Company Buy Ratings Hold Ratings Sell Ratings SNNUFSmith & Nephew PLC0 0 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is SNNUF or BDRX More Risky?
Smith & Nephew PLC has a beta of 0.662, which suggesting that the stock is 33.815% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.460, suggesting its more volatile than the S&P 500 by 46.046%.
-
Which is a Better Dividend Stock SNNUF or BDRX?
Smith & Nephew PLC has a quarterly dividend of $0.14 per share corresponding to a yield of 3.07%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew PLC pays 124.34% of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNNUF or BDRX?
Smith & Nephew PLC quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals PLC quarterly revenues of --. Smith & Nephew PLC's net income of -- is lower than Biodexa Pharmaceuticals PLC's net income of --. Notably, Smith & Nephew PLC's price-to-earnings ratio is 34.07x while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew PLC is 1.89x versus 4.01x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNNUFSmith & Nephew PLC1.89x 34.07x -- -- BDRXBiodexa Pharmaceuticals PLC4.01x -- -- --
-
Which has Higher Returns SNNUF or NCNA?
NuCana PLC has a net margin of -- compared to Smith & Nephew PLC's net margin of --. Smith & Nephew PLC's return on equity of 5.85% beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SNNUFSmith & Nephew PLC-- -- $8.7B NCNANuCana PLC-- -$2.28 -- -
What do Analysts Say About SNNUF or NCNA?
Smith & Nephew PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand NuCana PLC has an analysts' consensus of $64.50 which suggests that it could grow by 4978.74%. Given that NuCana PLC has higher upside potential than Smith & Nephew PLC, analysts believe NuCana PLC is more attractive than Smith & Nephew PLC.
Company Buy Ratings Hold Ratings Sell Ratings SNNUFSmith & Nephew PLC0 0 0 NCNANuCana PLC1 2 0 -
Is SNNUF or NCNA More Risky?
Smith & Nephew PLC has a beta of 0.662, which suggesting that the stock is 33.815% less volatile than S&P 500. In comparison NuCana PLC has a beta of 0.973, suggesting its less volatile than the S&P 500 by 2.67%.
-
Which is a Better Dividend Stock SNNUF or NCNA?
Smith & Nephew PLC has a quarterly dividend of $0.14 per share corresponding to a yield of 3.07%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew PLC pays 124.34% of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNNUF or NCNA?
Smith & Nephew PLC quarterly revenues are --, which are smaller than NuCana PLC quarterly revenues of --. Smith & Nephew PLC's net income of -- is lower than NuCana PLC's net income of -$5.9M. Notably, Smith & Nephew PLC's price-to-earnings ratio is 34.07x while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew PLC is 1.89x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNNUFSmith & Nephew PLC1.89x 34.07x -- -- NCNANuCana PLC-- -- -- -$5.9M
-
Which has Higher Returns SNNUF or VRNA?
Verona Pharma PLC has a net margin of -- compared to Smith & Nephew PLC's net margin of -763.91%. Smith & Nephew PLC's return on equity of 5.85% beat Verona Pharma PLC's return on equity of -74.15%.
Company Gross Margin Earnings Per Share Invested Capital SNNUFSmith & Nephew PLC-- -- $8.7B VRNAVerona Pharma PLC90.35% -$0.56 $250.5M -
What do Analysts Say About SNNUF or VRNA?
Smith & Nephew PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand Verona Pharma PLC has an analysts' consensus of $47.29 which suggests that it could grow by 5.53%. Given that Verona Pharma PLC has higher upside potential than Smith & Nephew PLC, analysts believe Verona Pharma PLC is more attractive than Smith & Nephew PLC.
Company Buy Ratings Hold Ratings Sell Ratings SNNUFSmith & Nephew PLC0 0 0 VRNAVerona Pharma PLC5 0 0 -
Is SNNUF or VRNA More Risky?
Smith & Nephew PLC has a beta of 0.662, which suggesting that the stock is 33.815% less volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.400, suggesting its less volatile than the S&P 500 by 60.012%.
-
Which is a Better Dividend Stock SNNUF or VRNA?
Smith & Nephew PLC has a quarterly dividend of $0.14 per share corresponding to a yield of 3.07%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew PLC pays 124.34% of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNNUF or VRNA?
Smith & Nephew PLC quarterly revenues are --, which are smaller than Verona Pharma PLC quarterly revenues of $5.6M. Smith & Nephew PLC's net income of -- is lower than Verona Pharma PLC's net income of -$43M. Notably, Smith & Nephew PLC's price-to-earnings ratio is 34.07x while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew PLC is 1.89x versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNNUFSmith & Nephew PLC1.89x 34.07x -- -- VRNAVerona Pharma PLC-- -- $5.6M -$43M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will American Tower Stock Recover?
The performance of the real estate investment trust, or REIT,…
Will Booking Holdings Stock Split?
Booking Holdings, the travel and technology company that owns brands…
Stock Ideas
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 125x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
NARI alert for Jan 7
Inari Medical [NARI] is up 22.02% over the past day.
Buy
70
PDEX alert for Jan 7
Pro-Dex [PDEX] is down 6.02% over the past day.
Buy
52
ALCO alert for Jan 7
Alico [ALCO] is down 0.67% over the past day.
